Predicting Impacts of the Pending COVID-19 Vaccination Campaign on Safety Reporting, Tracking, and Liability for the Entire Industry

Predicting Impacts of the Pending COVID-19 Vaccination Campaign on Safety Reporting, Tracking, and Liability for the Entire Industry

Whitepapers

This whitepaper, developed in partnership with Sidley Austin LLP, provides an in-depth analysis of the impact of the COVID-19 mass vaccination campaigns on pharmacovigilance teams, including:

  • The mass influx of adverse events reported within a short period of time
  • The need for rapid signal evaluation and impact assessments
  • Increased liability risks given the prominence and scale of the vaccination programs

Download this whitepaper to learn why pharmacovigilance departments for all pharmaceutical companies, regardless of whether they are a COVID-19 manufacturer, must be prepared for the anticipated surge in adverse event reporting.

Keep informed

For expert insight and updates from the MyMeds&Me team.

We respect your privacy and we will only use your email address for newsletters and company updates